The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2022 | RATIONALE-306: Asian subgroup of 1L tislelizumab + chemo vs chemo alone for esophageal SCC
Ken Kato, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, discusses results from the Asian subgroup of the global, randomized, Phase III RATIONALE-306 trial (NCT03783442), which compared tislelizumab plus chemotherapy vs chemotherapy alone in the first-line setting for patients with advanced/metastatic esophageal squamous cell carcinoma. There were 4 different chemotherapy regimens used in the trial, which sets this trial apart from other trials investigating the same area. A notable aspect of the results was the hazard ratios of the PD-L1-negative and PD-L1-positive populations. Similar clinical trials have previously showed worse hazard ratios in the PD-L1-negative population, compared to PD-L1-positive, however in this trial the hazard ratio in the PD-L1-negative and PD-L1-positive populations were similar. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
